Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress.

Westergard T, McAvoy K, Russell K, Wen X, Pang Y, Morris B, Pasinelli P, Trotti D, Haeusler A.

EMBO Mol Med. 2019 Jan 7. pii: e9423. doi: 10.15252/emmm.201809423. [Epub ahead of print]

2.

Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene.

Wen X, Westergard T, Pasinelli P, Trotti D.

Neurosci Lett. 2017 Jan 1;636:16-26. doi: 10.1016/j.neulet.2016.09.007. Epub 2016 Sep 13. Review.

3.

Cell-to-Cell Transmission of Dipeptide Repeat Proteins Linked to C9orf72-ALS/FTD.

Westergard T, Jensen BK, Wen X, Cai J, Kropf E, Iacovitti L, Pasinelli P, Trotti D.

Cell Rep. 2016 Oct 11;17(3):645-652. doi: 10.1016/j.celrep.2016.09.032.

4.

Correction: Interactions of L-3,5,3'-Triiodothyronine, Allopregnanolone, and Ivermectin with the GABAA Receptor: Evidence for Overlapping Intersubunit Binding Modes.

Westergard T, Salari R, Martin JV, Brannigan G.

PLoS One. 2015 Nov 3;10(11):e0142514. doi: 10.1371/journal.pone.0142514. eCollection 2015. No abstract available.

5.

Interactions of L-3,5,3'-Triiodothyronine [corrected], Allopregnanolone, and Ivermectin with the GABAA Receptor: Evidence for Overlapping Intersubunit Binding Modes.

Westergard T, Salari R, Martin JV, Brannigan G.

PLoS One. 2015 Sep 30;10(9):e0139072. doi: 10.1371/journal.pone.0139072. eCollection 2015. Erratum in: PLoS One. 2015;10(11):e0142514.

6.

Taspase1-dependent TFIIA cleavage coordinates head morphogenesis by limiting Cdkn2a locus transcription.

Takeda S, Sasagawa S, Oyama T, Searleman AC, Westergard TD, Cheng EH, Hsieh JJ.

J Clin Invest. 2015 Mar 2;125(3):1203-14. doi: 10.1172/JCI77075. Epub 2015 Feb 9.

7.

Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death.

Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, Pasinelli P, Ichida JK, Trotti D.

Neuron. 2014 Dec 17;84(6):1213-25. doi: 10.1016/j.neuron.2014.12.010.

8.

Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ.

Cancer Cell. 2014 Apr 14;25(4):530-42. doi: 10.1016/j.ccr.2014.03.008.

9.

A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.

Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, Cheng EH, Hsieh JJ.

Cancer Res. 2012 Feb 1;72(3):736-46. doi: 10.1158/0008-5472.CAN-11-2584. Epub 2011 Dec 13.

10.

Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint.

Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK, Cheng EH, Hsieh JJ.

Nature. 2010 Sep 16;467(7313):343-6. doi: 10.1038/nature09350. Epub 2010 Sep 5.

11.

The VDAC2-BAK rheostat controls thymocyte survival.

Ren D, Kim H, Tu HC, Westergard TD, Fisher JK, Rubens JA, Korsmeyer SJ, Hsieh JJ, Cheng EH.

Sci Signal. 2009 Aug 25;2(85):ra48. doi: 10.1126/scisignal.2000274.

12.

MLL5 governs hematopoiesis: a step closer.

Liu H, Westergard TD, Hsieh JJ.

Blood. 2009 Feb 12;113(7):1395-6. doi: 10.1182/blood-2008-11-185801.

13.

The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage.

Tu HC, Ren D, Wang GX, Chen DY, Westergard TD, Kim H, Sasagawa S, Hsieh JJ, Cheng EH.

Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1093-8. doi: 10.1073/pnas.0808173106. Epub 2009 Jan 14.

14.

Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.

Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ.

Genes Dev. 2006 Sep 1;20(17):2397-409.

15.

Acute psychotic disorders treated with 5% zuclopenthixol acetate in 'Viscoleo' ('Cisordinol-Acutard'), a global assessment of the clinical effect: an open multi-centre study.

Løwert AC, Rasmussen EM, Holm R, Almbjerg F, Calberg H, Joensen A, Nimb M, Baden H, Andersen E, Westergård T, et al.

Pharmatherapeutica. 1989;5(6):380-6.

PMID:
2687895

Supplemental Content

Loading ...
Support Center